DK3224268T3 - Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser - Google Patents

Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser Download PDF

Info

Publication number: DK3224268T3
Authority: DK; Denmark
Prior art keywords: sterphosphoramidate; deoxyadenosin; derivatives; new; amino acid
Prior art date: 2014-11-28

Application number

DK15804216.8T

Other languages

English (en)

Inventor

Hugh Griffith

Christopher Mcguigan

Valentina Ferrari

Michaela Serpi

Antunez Carmen Jimenez

Original Assignee

NuCana plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-28

Filing date

2015-11-27

Publication date

2019-09-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3224268(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-11-28 Priority claimed from GBGB1421211.2A external-priority patent/GB201421211D0/en

2015-11-02 Priority claimed from GBGB1519316.2A external-priority patent/GB201519316D0/en

2015-11-27 Application filed by NuCana plc filed Critical NuCana plc

2019-09-02 Application granted granted Critical

2019-09-02 Publication of DK3224268T3 publication Critical patent/DK3224268T3/da

Links

230000001093 anti-cancer Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical class C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DK15804216.8T 2014-11-28 2015-11-27 Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser DK3224268T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1421211.2A GB201421211D0 (en)	2014-11-28	2014-11-28	Chemical compounds
GBGB1519316.2A GB201519316D0 (en)	2015-11-02	2015-11-02	Chemical compounds
PCT/GB2015/053628 WO2016083830A1 (en)	2014-11-28	2015-11-27	New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds

Publications (1)

Publication Number	Publication Date
DK3224268T3 true DK3224268T3 (da)	2019-09-02

Family

ID=54771155

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15804216.8T DK3224268T3 (da)	2014-11-28	2015-11-27	Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser

Country Status (26)

Country	Link
US (3)	US10570168B2 (da)
EP (2)	EP3224268B1 (da)
JP (2)	JP6646668B2 (da)
KR (2)	KR102741202B1 (da)
CN (2)	CN111909231B (da)
AU (2)	AU2015352203B2 (da)
CA (1)	CA2962373C (da)
CL (1)	CL2017001336A1 (da)
CY (1)	CY1122074T1 (da)
DK (1)	DK3224268T3 (da)
EA (1)	EA031727B1 (da)
ES (1)	ES2742167T3 (da)
HR (1)	HRP20191461T1 (da)
HU (1)	HUE046850T2 (da)
IL (4)	IL291927A (da)
LT (1)	LT3224268T (da)
ME (1)	ME03462B (da)
MX (3)	MX394059B (da)
PH (1)	PH12017500944B1 (da)
PL (1)	PL3224268T3 (da)
PT (1)	PT3224268T (da)
RS (1)	RS59264B1 (da)
SG (2)	SG11201702369UA (da)
SI (1)	SI3224268T1 (da)
SM (1)	SMT201900489T1 (da)
WO (1)	WO2016083830A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2569185T3 (es)	2011-03-01	2016-05-09	Nucana Biomed Limited	Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
HRP20191461T1 (hr)	2014-11-28	2019-11-15	NuCana plc	Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
GB201522764D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Formulations of phosphate derivatives
GB201609600D0 (en) *	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Cancer treatments
GB201609601D0 (en)	2016-06-01	2016-07-13	Nucana Biomed Ltd	Phosphoramidate compounds
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
GB201720279D0 (en)	2017-12-05	2018-01-17	Nucana Biomed Ltd	Anticancer compounds
CN110669088B (zh) *	2018-07-02	2023-03-28	成都阿奇生物医药科技有限公司	N-(2-乙基胺)苯磺酰胺基虫草素衍生物及其制备方法和应用
GB201904544D0 (en)	2019-04-01	2019-05-15	NuCana plc	Anticancer compounds
CN111888373A (zh) *	2019-05-05	2020-11-06	上海医药集团股份有限公司	一种虫草素或其药学上可接受的盐的应用
KR20250012582A (ko)	2022-05-12	2025-01-24	뉴카나 피엘씨	암 치료
CN116768949B (zh) *	2022-07-12	2026-03-03	南京工业大学	一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物
WO2025058573A1 (en) *	2023-09-15	2025-03-20	National Science And Technology Development Agency	Cordycepin derivatives or a pharmaceutically acceptable salt thereof as pan-antiviral agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4357324A (en)	1981-02-24	1982-11-02	The United States Of America As Represented By The Department Of Health And Human Services	Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
EP1827460A4 (en) *	2004-12-09	2012-03-14	Univ Minnesota	NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
GB0505781D0 (en) *	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
WO2006121820A1 (en) *	2005-05-05	2006-11-16	Valeant Research & Development	Phosphoramidate prodrugs for treatment of viral infection
GB0623493D0 (en)	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
BRPI1004575A2 (pt)	2009-01-09	2016-04-05	Inhibitex Inc	composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
CA2751458C (en)	2009-02-06	2018-06-05	Rfs Pharma, Llc	Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
WO2010108140A1 (en)	2009-03-20	2010-09-23	Alios Biopharma, Inc.	Substituted nucleoside and nucleotide analogs
EA025311B1 (ru)	2010-07-19	2016-12-30	Гайлид Сайэнсиз, Инк.	Способы получения диастереомерно чистых фосфорамидатных пролекарств
US20120070411A1 (en) *	2010-09-22	2012-03-22	Alios Biopharma, Inc.	Substituted nucleotide analogs
WO2012040127A1 (en) *	2010-09-22	2012-03-29	Alios Biopharma, Inc.	Substituted nucleotide analogs
GB201016855D0 (en)	2010-10-06	2010-11-17	Nucana Biomed Ltd	Chemical compounds
ES2569185T3 (es)	2011-03-01	2016-05-09	Nucana Biomed Limited	Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
US20140286903A1 (en) *	2011-11-10	2014-09-25	Inhibitex, Inc.	Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections
TW201542581A (zh) *	2013-09-11	2015-11-16	艾默理大學	核苷酸與核苷治療組成物及其相關用途
JP2017504572A (ja)	2013-11-27	2017-02-09	アイデニクス・ファーマシューティカルズ・エルエルシー	肝臓癌治療のためのヌクレオチド類
EA033046B1 (ru)	2014-06-25	2019-08-30	НУКАНА ПиЭлСи	Состав, содержащий пролекарство гемцитабина
CN105646629A (zh)	2014-11-25	2016-06-08	广州市恒诺康医药科技有限公司	L-核苷类化合物及其应用
HRP20191461T1 (hr) *	2014-11-28	2019-11-15	NuCana plc	Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja
WO2016145142A1 (en)	2015-03-10	2016-09-15	Emory University	Nucleotide and nucleoside therapeutics compositions and uses related thereto
CN107835687A (zh)	2015-05-14	2018-03-23	努卡那有限公司	癌症治疗
GB201522764D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Formulations of phosphate derivatives
GB201609600D0 (en)	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Cancer treatments
GB201609601D0 (en)	2016-06-01	2016-07-13	Nucana Biomed Ltd	Phosphoramidate compounds
GB201609602D0 (en)	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Chemical compounds
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
GB201720279D0 (en)	2017-12-05	2018-01-17	Nucana Biomed Ltd	Anticancer compounds

2015
- 2015-11-27 HR HRP20191461 patent/HRP20191461T1/hr unknown
- 2015-11-27 PH PH1/2017/500944A patent/PH12017500944B1/en unknown
- 2015-11-27 EP EP15804216.8A patent/EP3224268B1/en active Active
- 2015-11-27 US US15/518,527 patent/US10570168B2/en active Active
- 2015-11-27 CN CN202010794701.2A patent/CN111909231B/zh active Active
- 2015-11-27 PL PL15804216T patent/PL3224268T3/pl unknown
- 2015-11-27 MX MX2020010375A patent/MX394059B/es unknown
- 2015-11-27 SG SG11201702369UA patent/SG11201702369UA/en unknown
- 2015-11-27 IL IL291927A patent/IL291927A/en unknown
- 2015-11-27 CA CA2962373A patent/CA2962373C/en active Active
- 2015-11-27 PT PT15804216T patent/PT3224268T/pt unknown
- 2015-11-27 EA EA201791182A patent/EA031727B1/ru unknown
- 2015-11-27 ES ES15804216T patent/ES2742167T3/es active Active
- 2015-11-27 ME MEP-2019-230A patent/ME03462B/me unknown
- 2015-11-27 SG SG10202009020VA patent/SG10202009020VA/en unknown
- 2015-11-27 EP EP19181028.2A patent/EP3683225A1/en active Pending
- 2015-11-27 KR KR1020237021261A patent/KR102741202B1/ko active Active
- 2015-11-27 AU AU2015352203A patent/AU2015352203B2/en active Active
- 2015-11-27 CN CN201580063936.1A patent/CN107207554B/zh active Active
- 2015-11-27 LT LTEP15804216.8T patent/LT3224268T/lt unknown
- 2015-11-27 DK DK15804216.8T patent/DK3224268T3/da active
- 2015-11-27 HU HUE15804216A patent/HUE046850T2/hu unknown
- 2015-11-27 SM SM20190489T patent/SMT201900489T1/it unknown
- 2015-11-27 WO PCT/GB2015/053628 patent/WO2016083830A1/en not_active Ceased
- 2015-11-27 MX MX2017006942A patent/MX375759B/es active IP Right Grant
- 2015-11-27 JP JP2017528423A patent/JP6646668B2/ja active Active
- 2015-11-27 RS RSP20191057 patent/RS59264B1/sr unknown
- 2015-11-27 SI SI201530848T patent/SI3224268T1/sl unknown
- 2015-11-27 KR KR1020177014174A patent/KR102548806B1/ko active Active
2017
- 2017-03-23 IL IL251353A patent/IL251353B/en active IP Right Grant
- 2017-05-24 CL CL2017001336A patent/CL2017001336A1/es unknown
- 2017-05-26 MX MX2022008744A patent/MX2022008744A/es unknown
2019
- 2019-08-13 CY CY20191100874T patent/CY1122074T1/el unknown
- 2019-09-20 AU AU2019232929A patent/AU2019232929B2/en active Active
2020
- 2020-01-10 JP JP2020002722A patent/JP6978524B2/ja active Active
- 2020-02-05 US US16/782,952 patent/US11352387B2/en active Active
- 2020-07-16 IL IL276109A patent/IL276109B/en unknown
2022
- 2022-04-07 IL IL292062A patent/IL292062B2/en unknown
- 2022-06-06 US US17/833,780 patent/US12054510B2/en active Active

Also Published As

Publication number	Publication date
EP3224268A1 (en)	2017-10-04
IL276109B (en)	2022-05-01
NZ730919A (en)	2021-02-26
EP3683225A1 (en)	2020-07-22
SG10202009020VA (en)	2020-10-29
CN107207554B (zh)	2020-09-11
WO2016083830A1 (en)	2016-06-02
BR112017011187A2 (pt)	2018-01-02
IL291927A (en)	2022-06-01
ES2742167T3 (es)	2020-02-13
MX2020010375A (es)	2022-07-19
US12054510B2 (en)	2024-08-06
CN111909231A (zh)	2020-11-10
EP3224268B1 (en)	2019-06-26
JP2017535587A (ja)	2017-11-30
PT3224268T (pt)	2019-09-04
MX2022008744A (es)	2022-07-27
PH12017500944B1 (en)	2023-03-08
CN111909231B (zh)	2025-10-17
IL292062B2 (en)	2023-06-01
HUE046850T2 (hu)	2020-03-30
IL292062A (en)	2022-06-01
AU2019232929B2 (en)	2020-09-10
US11352387B2 (en)	2022-06-07
ME03462B (me)	2020-01-20
JP2020075928A (ja)	2020-05-21
CN107207554A (zh)	2017-09-26
KR102548806B1 (ko)	2023-06-27
EA031727B1 (ru)	2019-02-28
AU2015352203A1 (en)	2017-04-27
SMT201900489T1 (it)	2019-11-13
PH12017500944A1 (en)	2017-11-20
US20200181189A1 (en)	2020-06-11
US10570168B2 (en)	2020-02-25
KR102741202B1 (ko)	2024-12-19
AU2015352203B2 (en)	2019-08-15
EA201791182A1 (ru)	2017-09-29
IL251353A0 (en)	2017-05-29
AU2019232929A1 (en)	2019-10-10
CY1122074T1 (el)	2020-11-25
MX394059B (es)	2025-03-24
IL251353B (en)	2020-08-31
JP6978524B2 (ja)	2021-12-08
CL2017001336A1 (es)	2017-12-15
LT3224268T (lt)	2019-09-25
RS59264B1 (sr)	2019-10-31
SI3224268T1 (sl)	2019-10-30
MX2017006942A (es)	2017-08-24
JP6646668B2 (ja)	2020-02-14
PL3224268T3 (pl)	2019-11-29
CA2962373C (en)	2023-04-25
KR20230098915A (ko)	2023-07-04
KR20170087465A (ko)	2017-07-28
US20220306675A1 (en)	2022-09-29
CA2962373A1 (en)	2016-06-02
HRP20191461T1 (hr)	2019-11-15
MX375759B (es)	2025-03-06
US20170253629A1 (en)	2017-09-07
SG11201702369UA (en)	2017-04-27
IL276109A (en)	2020-08-31
NZ767066A (en)	2022-03-25

Publication	Publication Date	Title
NO2025025I1 (no)	2025-06-05	Lazertinib in all its forms protected by the basic patent
HUE056634T2 (hu)	2022-02-28	Rákellenes szerekként hasznos szubsztituált karbonukleozid-származékok
DK3094631T4 (da)	2025-03-03	Pyrimidinyloxybenzenderivater som herbicider
DK3130592T3 (da)	2019-11-04	ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER
DK3302448T3 (da)	2024-02-05	Erstattede heterocyclylafledninger som cdk-inhibitore
HUE058009T2 (hu)	2022-06-28	1,3-Tiazol-2-il szubsztituált benzamid-származékok
DK3229810T3 (da)	2020-08-17	Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
SMT202400518T1 (it)	2025-01-14	Composizioni anticancro
ME03462B (me)	2020-01-20	NOVI 2' l/ILl 5' DERIVATI 3'-DEOKSI ADENOZINA SUPSTITUISANI AMINOKISELINSKIM ESTROM FOSFORAMIDATA, KAO ANTIKANCERSKA JEDINJENJA
LT3226843T (lt)	2021-08-10	Priešvėžinės kompozicijos
LT3226842T (lt)	2021-03-25	Priešvėžinės kompozicijos
HUE054534T2 (hu)	2021-09-28	Piridonszármazék tetrahidropiranil-metil csoporttal
BR112016025659A2 (pt)	2017-08-15	compostos, seus usos, e composições farmacêuticas para induzir condrogênese
EP3685682C0 (en)	2023-06-07	Oral rehydration composition
HUE050974T2 (hu)	2021-01-28	Eljárás pirimidinszulfamid-származékok elõállítására
DK3153508T3 (da)	2020-05-18	Naphthofuranderivater til anvendelse som anticancermidler
PL3207149T3 (pl)	2023-08-21	Kompozycja farmaceutyczna o zwiększonej stabilności
IL259632B (en)	2022-03-01	Haemorrhage avoiding microelectrode
LT3341380T (lt)	2020-01-10	Chromono oksimo darinys, prasiskverbiantis į smegenis, skirtas levadopa sukeltos diskinezijos gydymui
DK3186227T3 (da)	2021-04-26	Nye sulfonylaminobenzamid-forbindelser som anthelmintika
LT3389633T (lt)	2021-09-10	Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį
EP3171860C0 (en)	2024-12-11	SOLID ORAL FORMULATION OF FENRETINIDE
LT3097076T (lt)	2019-08-26	Nauji cip-eikozanoidų dariniai
DK3199160T3 (da)	2020-04-20	Vandig sammensætning
DK3138840T3 (da)	2020-12-21	Thiadiazolidin-derivat som anti-enterovirus 71